

Remedy Pharmaceuticals Files Investigational New Drug Application with FDA

Lead product moves into human clinical development.

New York, NY, USA - December 23, 2009 – Remedy Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the FDA in regards to its lead product, RP-1127.

It is expected that the IND will support clinical studies in stroke, traumatic brain injury, and spinal cord injury.

This filing represents the culmination of two years of preclinical animal testing, and efforts in drug formulation, manufacturing, and stability testing. The FDA has 30 days to review Remedy's IND application and to request any additional information before allowing the clinical trial to proceed. It is expected that subject to FDA's approval, patient recruitment for a Phase 1 study of the safety and tolerability of RP-1127 in healthy volunteers will begin in the first quarter of 2010.

"The filing of the RP-1127 IND marks an important transition for Remedy as our lead product moves into human clinical development," said Sven Jacobson, Chief Executive Officer of Remedy. "We are confident that our data package and proposed study will be acceptable to FDA and look forward to enrolling patients into the Phase 1 study."

About RP-1127

Remedy's lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of NC_{Ca-ATP} channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

About Remedy Pharmaceuticals

Remedy Pharmaceuticals, Inc. is a development stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: info@remedypharmaceuticals.com